Odyssey Therapeutics, Inc. 8K

Odyssey Therapeutics reported Q2 2026 results, outlining progress and timelines for its OD-001 and OD-002 clinical programs and affirming cash runway into the second half of 2028.

On August 4, 2026, Odyssey Therapeutics, Inc. reported its financial results for the quarter ended June 30, 2026 and provided a corporate update, highlighting completion of treatment in the Phase 2a expansion cohort for its lead RIPK2 inhibitor OD-001 with additional data to be presented at United European Gastroenterology Week in October, plans to initiate a Phase 2b monotherapy trial and a Phase 2a combination trial with vedolizumab for OD-001 in the second half of 2026, plans to file a clinical trial application for its second program OD-002 in the second half of 2026 to enable a Phase 1/2a trial in 2027, and a reported cash, cash equivalents and marketable securities balance of $433.1 million as of June 30, 2026 expected to fund operations into the second half of 2028 alongside increased R&D spending and a GAAP net loss of $52.8 million (adjusted net loss of $38.4 million) for the quarter.

Filing Facts

CIK

1882782

Ticker

ODTX

Form

8K

Source Type

fda

Accession

0001193125-26-331512

Alert Tier

6